Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-023864
Filing Date
2025-08-14
Accepted
2025-08-14 13:56:28
Documents
66
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 1126385
2 EX-31.1 ex31-1.htm EX-31.1 18054
3 EX-31.2 ex31-2.htm EX-31.2 17394
4 EX-32 ex32.htm EX-32 7943
  Complete submission text file 0001641172-25-023864.txt   5551685

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE pvct-20250630.xsd EX-101.SCH 40602
6 XBRL CALCULATION FILE pvct-20250630_cal.xml EX-101.CAL 62671
7 XBRL DEFINITION FILE pvct-20250630_def.xml EX-101.DEF 161686
8 XBRL LABEL FILE pvct-20250630_lab.xml EX-101.LAB 335279
9 XBRL PRESENTATION FILE pvct-20250630_pre.xml EX-101.PRE 262124
68 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 869828
Mailing Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929
Business Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929 (866) 594-5999
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

EIN.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36457 | Film No.: 251217235
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)